IP Library Granted Patent US 9,814,678
Granted Patent B2
US 9,814,678 · App. 14/302,742 · Granted Nov 14, 2017

Sustained release particle formulations

Inventors: Cory Berkland (Lawrence, KS); Milind Singh (Mission, KS)
Assignee: ORBIS BIOSCIENCES, INC.
A61K9/145A61K9/146A61K9/1611A61K9/1617A61K9/1652A61K31/09A61K31/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,814,678
App. No.
14/302,742
Granted
Nov 14, 2017
Kind
B2
Abstract

Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles.

Claims (37)

1. A method comprising:

mixing a hydrophilic active ingredient, a hydrophobic matrix material, a stabilizer, and a release modifier at a temperature sufficient to melt the hydrophobic matrix thereby forming a particle mixture;

fabricating particles from the particle mixture, wherein the particles have a particle diameter from about 50 μm to about 300 μm, and wherein the stabilizer is disposed within the hydrophobic matrix material of the particles;

allowing the particles to cool to room temperature; and

subsequently heating the particles to a temperature that is slightly below the melting temperature of the component of the particle having the lowest melting temperature, wherein the subsequent heating step reduces the occurrence of pores on the surface of the particle.

2. The method of claim 1 , wherein the hydrophobic matrix, active ingredient, and the release modifier are mixed followed by addition of the stabilizer.

3. The method of claim 1 , wherein the release modifier and the stabilizer are mixed followed by addition of the active ingredient and hydrophobic matrix.

4. A method comprising:

melting together a hydrophilic active ingredient, a hydrophobic matrix comprising a hydrophobic wax material or a lipid material, and one or more of a release modifier and a stabilizer added to the hydrophobic matrix to form a particle mixture comprising 20 to about 60 weight % of the hydrophilic active agent, 40 to about 80 weight % of the hydrophobic wax material, about 0.5 to about 10 weight % of release modifier when present, and about 0.5 to about 10 weight % of stabilizer when present; wherein the hydrophilic active ingredient is dispersed in the hydrophobic matrix;

fabricating particles from the particle mixture to have a mean particle diameter from about 50 μm to about 300 μm;

allowing the particles to cool to room temperature; and

subsequently heating the particles to a temperature that is slightly below the melting temperature of a component of the particle having the lowest melting temperature, wherein the component includes the hydrophilic active ingredient, the hydrophobic matrix, the stabilizer when present and the release modifier when present, and wherein the subsequent heating step reduces the occurrence of pores on the surface of the particle.

5. The method of claim 4 , wherein the hydrophobic matrix, active ingredient, and the release modifier are melted together followed by addition of the stabilizer.

6. The method of claim 4 , wherein the release modifier and the stabilizer are melted together followed by addition of the active ingredient and hydrophobic matrix.

7. The method of claim 4 , wherein the active ingredient has a melting point at or below about 250° C.

8. The method of claim 4 , wherein the hydrophobic matrix comprises a hydrophobic wax material.

9. The method of claim 4 , further comprising allowing the particles to cool and applying an additional layer or coating to the particles.

10. The method of claim 4 wherein the release modifier and the stabilizer are melted together and the hydrophobic matrix and the active ingredient are then added.

11. The method of claim 10 wherein the release modifier is selected from the group consisting of stearic acid, sodium stearate, magnesium stearate, glyceryl monostearate, cremophor (castor oil), oleic acid, sodium oleate, lauric acid, sodium laurate, myristic acid, sodium myristate, vegetable oils, coconut oil, mono-, di-, tri-glycerides, stearyl alcohol, span 20, span 80, and polyethylene glycol (PEG).

12. The method of claim 10 wherein the release modifier is stearic acid.

13. The method of claim 10 wherein the stabilizer is selected from the group consisting of cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, microcrystalline cellulose, cellulose acetate, cellulose phthalate, methyl cellulose, chitin, chitosan, pectin, polyacrylates, polymethacrylates, polyvinyl acetate, EVA resins, acetate phthalate, polyanhydrides. polyvinylalcohols, and silicone elastomers.

14. The method of claim 10 wherein the stabilizer is ethyl cellulose.

15. The method of claim 8 wherein the hydrophobic matrix comprises a wax selected from the group consisting of ceresine wax, beeswax, ozokerite, microcrystalline wax, candelilla wax, montan wax, carnauba wax, paraffin wax, cauassu wax, Japan wax, and Shellac wax.

16. The method of claim 8 wherein the hydrophobic wax material is carnauba wax.

17. The method of claim 16 wherein the release modifier is added, and wherein the release modifier is stearic acid.

18. The method of claim 17 wherein the stabilizer is added, and wherein the stabilizer is ethyl cellulose.

19. The method of claim 4 wherein the particles fabricated have a mean particle diameter of from about 50 μm to about 300 μm, and wherein the particle diameter size distribution has a standard deviation no more than 25% from the mean particle diameter.

20. The method of claim 4 wherein the particles fabricated have a mean particle diameter of from about 150 μm to about 250 μm, and wherein the particle diameter size distribution has a standard deviation no more than 25% from the mean particle diameter.

21. The method of claim 4 wherein the particles fabricated have a mean particle diameter of from about 50 μm to about 300 μm, and wherein the particle diameter size distribution has a standard deviation no more than 10% from the mean particle diameter.

22. The method of claim 4 wherein the particles fabricated have a mean particle diameter of from about 150 μm to about 250 μm, and wherein the particle diameter size distribution has a standard deviation no more than 10% from the mean particle diameter.

23. The method of claim 4 , wherein the hydrophobic matrix comprises a lipid material chosen from one or more of glycerol fatty acid esters, triacylglycerols, tripalmitin, tristearin, glyceryl trilaurate, coconut oil, hydrogenated fats, ceramides, and organic esters.

24. The method of claim 4 , wherein the temperature at which the particles are subsequently heated is 65° C.

25. The method of claim 4 , wherein the temperature at which the particles are subsequently heated is 60° C.

26. The method of claim 4 , wherein the temperature at which the particles are subsequently heated is slightly lower than the melting temperature of the hydrophobic matrix.

27. The method of claim 4 , wherein the subsequent heating step is performed 6 to 24 hours after the fabrication step.

28. The method of claim 4 , wherein the subsequent heating step is performed for a period of 1 hour.

29. The method of claim 4 , wherein the subsequent heating step is performed for a period of 3 hours.

Assignments (7)
SECURITY INTEREST Recorded Nov 8, 2022
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: TEAL MIDCO HOLDINGS, L.P.
Reel/Frame 061698/0541 →
CHANGE OF NAME Recorded Sep 24, 2020
From: ORBIS BIOSCIENCES, INC.
To: ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053868/0027 →
SECURITY INTEREST Recorded Sep 22, 2020
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: CRESCENT AGENCY SERVICES LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 053849/0967 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAMES 037246/0313, 047807/0967, 053474/0276 Recorded Sep 22, 2020
From: BANK OF MONTREAL, AS COLLATERAL AGENT
To: ADARE PHARMACEUTICALS, INC.; ADARE DEVELOPMENT I, L.P.; ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053852/0697 →
SECURITY INTEREST Recorded Aug 12, 2020
From: ADARE PHARMACEUTICALS USA, INC.
To: BANK OF MONTREAL
Reel/Frame 053474/0276 →
CHANGE OF ADDRESS Recorded Jul 23, 2019
From: ORBIS BIOSCIENCES, INC.
To: ORBIS BIOSCIENCES, INC.
Reel/Frame 049840/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2014
From: BERKLAND, CORY; SINGH, MILIND
To: ORBIS BIOSCIENCES, INC.
Reel/Frame 033837/0322 →
Continuity (3)
Continuation PCTUS2012069287 · Dec 12, 2012
Provisional Application 61569655 · Dec 12, 2011
Related Publication 20140294980A1 · Oct 2, 2014